Olema Oncology to Participate at Upcoming Virtual Investor Conferences
Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company, will participate in two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company, will participate in two upcoming virtual investor conferences. On March 2, 2021, CEO Sean P. Bohen will join a breast cancer panel at the Cowen 41st Annual Health Care Conference. Following that, on March 15, 2021, he will participate in a women's health panel at the 33rd Annual ROTH Growth Conference. Olema focuses on targeted therapies for women’s cancers, with its lead product OP-1250 currently undergoing a Phase 1/2 trial for ER-positive breast cancer.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was -15.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will participate at the following upcoming virtual investor conferences:
Cowen 41st Annual Health Care Conference
Date and Time: March 2, 2021 at 2:10 p.m. Eastern Time
Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual breast cancer panel discussion.
33rd Annual ROTH Growth Conference
Date and Time: March 15, 2021 at 5:00 p.m. Eastern Time
Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual women’s health panel discussion.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Contacts
Investor Contact:
ir@olema.com
Media Contact:
Sheryl Seapy, W2O
sseapy@w2ogroup.com
949-903-4750
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.